GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » Net Change in Cash

TSVT (2seventy bio) Net Change in Cash : $-31.79 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

2seventy bio's Net Change in Cash for the three months ended in Sep. 2024 was $-51.95 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was $-31.79 Mil.

2seventy bio Net Change in Cash Historical Data

The historical data trend for 2seventy bio's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2seventy bio Net Change in Cash Chart

2seventy bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial - - 130.45 -58.16 4.39

2seventy bio Quarterly Data
Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.53 -15.45 -19.66 55.27 -51.95

2seventy bio Net Change in Cash Calculation

2seventy bio's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-166.858+43.861+127.39+0
=4.39

2seventy bio's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-10.505+-41.497+0.052+0
=-51.95

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2seventy bio Net Change in Cash Related Terms

Thank you for viewing the detailed overview of 2seventy bio's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

2seventy bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » Net Change in Cash
Comparable Companies
CARM PLX CDXS TALS ABSI PEPG DSGN ADAP CTXR TRVI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
60 Binney Street, Cambridge, MA, USA, 02142
Website
https://www.2seventybio.com
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Executives
Marcela V. Maus director 16 RICHMOND CIRCLE, LEXINGTON MA 02421
Nick Leschly director, officer: President and CEO C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Baird William D Iii officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Philip D Gregory officer: Chief Scientific Officer POINT RICHMOND TECH CENTER II, 501 CANAL BOULEVARD SUITE A100, RICHMOND CA 94804
Kynam Capital Management, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Global Healthcare Master Fund, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Fund Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Yue Tang 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Nicola Heffron officer: Chief Operating Officer 2SEVENTY BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Daniel Lynch director
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Sarah Js Glickman director 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Ramy Ibrahim director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
William R. Sellers director C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142